tbuckley/cabot-search huggingface dataset:
AB0961 Comparison between Ultrasound B-Flow, Colour Doppler and Magnetic Resonance Imaging for Assessment of Tenosynovitis in The Hand of Rheumatoid Arthritis Patients - A Pilot Study
Authors: M. Ammitzbøll-Danielsen, D. Glinatsi, M. Østergaard, S. Torp-Pedersen, L. Terslev
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ultrasound (US) B-flow imaging (BFI) is a new technique for vascular imaging, based on US grey scale physics <sup>1</sup>. Therefore, Doppler artefacts such as aliasing, blooming and reverberations are not seen. Whether it is an alternative to Doppler for depicting inflammatory flow in the tendon sheath in rheumatoid arthritis patients (RA) is unknown. <h3>Objectives</h3> To evaluate US BFI for assessment of inflammatory activity in the tendon sheath compared to grey scale (GS), colour Doppler (CD) US and magnetic resonance imaging (MRI). <h3>Methods</h3> Ten RA patients with US-verified tenosynovitis were included. GS, CD and BFI assessment were performed using a GE Logiq E9 US unit with a high frequency linear 6–15 ML probe. BFI settings were adjusted to maximum sensitivity of 50, frequency at 12 MHz and dynamic range at 66. GS frequency was 15 MHz and CD settings according to published recommendations (ref). All settings were identical in all examinations. Axial T1-weighted pre- and post-contrast fat-saturated MR image sets (0.8mm slice thickness) were obtained using a Philips 1T MRI scanner (figure 1). One tendon sheath per patient was scored, in either the wrist or at the metacarpophalangeal joint level. CD, GS and MR images were scored for tenosynovitis 0–3 as proposed by the OMERACT US group and the OMERACT MRI in arthritis working group. BFI was scored peritendiniously as: 0: No flow, 1: Focal flow, 2: Multifocal flow, 3: Diffuse flow. Descriptive statistics were used for comparison of BFI, GS, CD and MRI scores. <h3>Results</h3> The mean (SD) score for the patients were 0.89 (0.74), 2.10 (0.74), 2.20 (0.92) and 2.30 (0.95) for BFI, GS, CD, and MRI, respectively. The difference between CD vs GS and MRI was never larger than ±1. The difference between CD and BFI was 1 in 5 patients and ≥2 in 3 patients (table 1). <h3>Conclusions</h3> BFI is a new imaging modality for visualization of perfusion. However, the presented results indicate that BFI is less sensitive to detect inflammation in the tendon sheath than CD, GS and MRI in RA patients. Further studies are required, in order to increase image optimization and flow sensitivity, but also to evaluate further use of BFI in diagnosis of inflammatory conditions. <h3>References</h3> Weskott HP. [B-flow–a new method for detecting blood flow]. Ultraschall in der Medizin (Stuttgart, Germany: 1980) 2000;21(2):59–65. <h3>Disclosure of Interest</h3> None declared
Summer music and arts festivals as hot spots for measles transmission: experience from England and Wales, June to October 2016
Authors: Olivier le Polain de Waroux, Vanessa Saliba, Simon Cottrell, Nick Young, Malorie Perry, Antoaneta Bukasa, Mary Ramsay, Kevin Brown, Gayatri Amirthalingam
Journal: Eurosurveillance (2016)

We report 52 cases of measles linked to music and arts festivals in England and Wales, between mid-June and mid-October 2016. Nearly half were aged 15 to 19 years. Several individuals who acquired measles at one festival subsequently attended another festival while infectious, resulting in multiple interlinked outbreaks. Transmission within festivals resulted in a geographical spread of cases nationally as well as internationally, which presents particular challenges for measles control.
The Association of the Polymorphisms of IMPDH1 Gene and Acute Graft-Versus-Host Disease After Related and Unrelated Hematopoietic Stem Cell Transplantation
Authors: Lifei Zhang, Haowen Xiao, Weijie Cao, Xiaoyu Lai, Yi Luo, Jimin Shi, Yamin Tan, Jingsong He, Wanzhuo Xie, Li Li, Xiaoli Zhu, Jie Sun, Guoqin Wei, Yingjia Wang, Xiaohong Yu, Zhen Cai, Maofang Lin, Xiujin Ye, He Huang
Journal: Blood (2010)
AB0837 Effects of Vitamin D Therapy on Quality of Life in Patients with fibromyalgia
Authors: A. Doğru, A. Balkarlı, V. Cobankara, M. Sahin, S.E. Tunc
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The role of vitamin D in the etiopathogenesis of fibromyalgia and non-specific musculoskeletal pain is controversial. <h3>Objectives</h3> In our study, we aimed to investigate the effect of vitamin D therapy on quality of life in patients with fibromyalgia. <h3>Methods</h3> 70 patients diagnosed with fibromyalgia and 65 age-sex match controls were included in the study. Patients were grouped as deficiency (&lt;20 ng/mL), inadequacy (20–30 ng/mL) and sufficient (&gt;30 ng/mL) according to the levels of vitamin D. Vitamin D replacement was performed for patients with deficiencies and inadequacies. Before and after vitamin D therapy, patients filled in the assessment tools. <h3>Results</h3> Vitamin D deficiencies and inadequacies were observed in 60% of the patients (n=42). Social function, mental health and vitality areas in patients9 quality of life forms were significantly lower in normal vitamin D group compared with low vitamin D group. In scales examined after Vitamin D replacement therapy, statistically significant differences were observed in the fibromyalgia impact questionnaire, Beck depression inventory, VAS and SF-36 compared to pre-treatment. <h3>Conclusions</h3> Since, vitamin D deficiency seems to be linked to the pathogenesis of FMS, serum vitamin D levels should be checked routinely as a general health problem and patients should be supplemented. <h3>Disclosure of Interest</h3> None declared
Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections
Authors: Tatsuo Oyake, Takayuki Masuda, Norifumi Sugawara, Maki Asahi, Yuzo Suzuki, Yoshiaki Okano, Yukiteru Fujishima, Yusei Aoki, Shugo Kowata, Shigeki Ito, Yoji Ishida
Journal: Blood (2015)
Repeating the success of the salt reduction programme
Authors: Alison E Tedstone
Journal: BMJ (2016)

Contrary to the suggestion that voluntary targets for the food industry won’t work,1 2 evidence shows that the gradual, voluntary approach to reformulation can be successful. Between 2001 and 2011 sodium intake in the UK fell significantly as the result of a national salt reduction programme.3 The programme encouraged reformulation of foods and was supported by a …
90Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose Therapy (HDT) Followed by Autologous Stem Cell Transplant (ASCT) May Improve Survival in Patients with Poor-Risk Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Retrospective Comparative Analysis.
Authors: Auayporn P. Nademanee, Amrita Krishnan, Nicole Tsai, Joycelynne Palmer, Arturo Molina, Henry C. Fung, David Yamauchi, Neil Martin Kogut, Stephen J. Forman, Andrew Raubitschek
Journal: Blood (2006)
Abstract 4514: Postoperative AV Block and Pacemaker Implantation after Transcatheter Aortic Valve Implantation
Authors: Sabine Bleiziffer, Hendrik Ruge, Jurgen Horer, Domenico Mazzitelli, Christian Schreiber, Andrea Hutter, Gernot Brockmann, Robert Bauernschmitt, Ruediger Lange
Journal: Circulation (2008)

High grade AV block and consecutive pacemaker (PM) implantation are frequent complications following transcatheter aortic valve implantation (TAVI). We aimed to identify risk factors predicting these complications. For logistic regression analysis, we included 85 patients (mean age 81±7y, EuroScore 24±15%) who underwent TAVI (n=73 transfemoral, n=2 via subclavian artery, n=10 transapical) between June 2007 and May 2008 and who had no previously implanted PM. Of those, 22 (26%) developed postoperative AV block with the need of PM implantation. PM implantation had to be performed more frequently in patients with pathological preoperative ECG findings, such as AV block °I (33% PM implantation) or bundle branch block (39% PM implantation) vs normal ECG (20% PM implantation, n.s.), and in patients receiving a CoreValve (28% PM implantation) vs an Edwards Sapien prosthesis (10% PM implantation, n.s.). Stepwise logistic regression analysis revealed the occurrence of a transient AV block &gt; °I during the TAVI procedure (52% PM implantation) as the only significant independent factor predicting later PM implantation (OR 8.98, CI 2.69 –29.98, p&lt;0.001), while gender, age, EuroScore, prosthesis type and dimensions, annulus diameter and preoperative ECG findings had no significant influence. Patients who experience a transient AV block &gt; °I during TAVI procedures should carefully be monitored postoperatively, as there is a 9fold increased risk of developing high grade AV block with the indication for a PM implantation.
Palmitoyl Acyltransferase DHHC9 Is Required for Efficient Induction of Leukemia By Oncogenic NRAS
Authors: Ping Liu, Bo Jiao, Ruihong Zhang, Huanbin Zhao, Chun Zhang, Min Wu, Qingsong Qiu, Donghe Li, Xuemei Zhao, Ruibao Ren
Journal: Blood (2014)
The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development
Authors: Sandra M. Wear, Paul G. Richardson, Carolyn Revta, Ravi Vij, Mark Fiala, Sagar Lonial, Alaina R. Mitchell, David S. Siegel, Adolfo Aleman, Andrzej J Jakubowiak, Diane E Durecki, Donna E. Reece, Engin Gul, Ajai Chari, Sundar Jagannath, Lisa La, Craig C. Hofmeister, Mindy A Bowers, A. Keith Stewart, Rachel Hagerty, Jeffrey L. Wolf, Geraldine Pelle-Day, Amrita Krishnan, Lupe Duarte, Todd M. Zimmerman, Daniel Larsen, Shaji Kumar, Ann Birgin, Noopur S. Raje, Vivek Roy, Michele Maharaj, Joseph W. Fay, Tracey Messing, Robert F Ott, Leah Tasca, Kenneth C. Anderson, Kathy Giusti
Journal: Blood (2011)
Equivalent Efficacy and Lower Toxicity of Subcutaneous Cladribine at Reduced Doses (Five versus Seven Consecutive days) in Hairy Cell Leukemia: An Interim Analysis of the ICGHCL 2004 Protocol by the Italian Cooperative Group on Hcl
Authors: Francesco Forconi, Francesco Zaja, Tamara Intermesoli, Luigi Rigacci, Caterina Stelitano, Silvia Tavera, Enrico Morello, Alessandro Pulsoni, Filippo Gherlinzoni, Alfonso Zaccaria, Anna Baraldi, Ivana Pierri, Renato Cantaffa, Giovanni Martinelli, Sara Barulli, Fortunato Morabito, Pier Luigi Zinzani, Mauro Spriano, Piero Galieni, Alessandra Caremani, Alice Pietrini, Emanuele Cencini, Maristella Tassi, Donatella Raspadori, Francesco Lauria
Journal: Blood (2008)
Treatment Response and Outcome in Childhood t(1;19)/TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group.
Authors: Leo Kager, Thomas Lion, Andishe Attarbaschi, Margit Koenig, Sabine Strehl, Oskar A. Haas, Michael N. Dworzak, Martin Schrappe, Helmut Gadner, Georg Mann
Journal: Blood (2005)
Expression of dlk1 in the Bone Marrow Cells of Patients with Myelodysplastic Syndrome and Its Clinical Significance
Authors: Zonghong Shao, Lanzhu Yue, Rong Fu, Lijuan Li, Erbao Ruan, Wen Qu, Yong Liang, Guojin Wang, Xiaoming Wang, Hong Liu, Jia Song, Yuhong Wu, Limin Xing, Jun Wang, Jing Guan, Huaquan Wang
Journal: Blood (2011)
Sam Everington: the proud generalist
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Gareth Iacobucci meets the pioneering east London GP who believes that primary care has finally arrived

“It was a complete shock to me and a lot of other people too, dare I say it. I initially left the letter alone because I thought it was a tax demand.”

Sam Everington’s reaction to being awarded a knighthood in 2015 for his services to primary care reflects an unpretentious yet determined demeanour that has helped propel him through a highly successful career.

His pioneering work at the Bromley by Bow Health Centre in Tower Hamlets, east London, is a shining beacon of holistic care in one of the country’s most deprived communities. In the centre, general practice coexists with more than 100 different community projects, including art therapy, a cafe, and a park.

Over his 30 year career Everington has deftly juggled his day job as a GP with other roles that include advising Labour and Conservative ministers who have come to observe his work.

But he’s no establishment figure. As a junior doctor in the late 1980s he slept outside the Royal London Hospital to protest against long working hours, and in 1993 he exposed the racial discrimination faced by doctors applying for hospital posts.1

Still …
FRI0291 Clinical Spectrum Time Course in Non Anti Jo-1 Positive Antisynthetase Syndrome: Table 1
Authors: L. Cavagna, H. Andersson, M.A. González-Gay, O. Molberg, F. Franceschini, I. Cavazzana, S. Castañeda, F.J. Lopez Longo, S. Balduzzi, C. Montecucco, K. Triantafyllias, J. Weinmann-Menke, J. Rojas-Serrano, A. Sifuentes Giraldo, J. Bachiller-Corral, F. Salaffi, F. Iannone, M. Giannini, L. Nuno, F. Bonella, U. Costabel, S. Parisi, C. Selmi, C. Scirè, M. Benucci, A. Doria, R. Caporali, D.I. Pérez-Román, A. Ghirardello
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The clinical phenotype of the antisynthetase syndrome (AS) has been related with the underlying autoantibody specificity. The typical disease triad (arthritis, myositis, and interstitial lung disease -ILD) is common in anti Jo-1 + AS, whereas isolated ILD is associated with anti PL-7 and PL-12 Ab. The majority of anti Jo-1 + patients without all triad findings at the onset (incomplete ASSD) will develop lacking features during the followup <h3>Objectives</h3> To assess the triad clinical spectrum time course in non anti Jo-1 + AS <h3>Methods</h3> The study cohort included patients + for anti-EJ, OJ, PL-7, or PL-12 Ab with at least 1 triad finding. Clinical features were retrospectively collected and analyzed <h3>Results</h3> we included 65 non anti Jo-1 + AS (7 anti EJ, 4 anti OJ, 30 anti PL-12, 24 anti PL-7; 49 females, 16 males). In median, age at disease onset was 53 years (IQR 42–64), diagnostic delay 9 months (IQR 3–23.5), followup 60 months (IQR 20.5–113). Patients9 characteristics are reported in Table 1. During the followup, 22/61 patients with incomplete AS developed new triad findings, in median 12 months (IQR 6–27) after disease onset. The frequency of incomplete AS developing new triad findings and the length of followup were significantly reduced in non anti Jo-1 + patients with respect to our corresponding anti Jo-1 + cohort (respectively: 22/61 vs 138/220, p&lt;0.001; median 60 months, IQR 18.5–113 vs median 75 months, IQR 39–134; p=0.002) <h3>Conclusions</h3> In non anti Jo-1 + patients the ex novo occurrence of classic triad finding is common, but less frequent than in anti Jo-1 + patients. The different length of followup may explain at least partly this difference <h3>References</h3> Cavagna L, et al. Medicine (Baltimore) 2015;94:e1144 <h3>Disclosure of Interest</h3> None declared
THU0139 Comparison of The Efficacy and Tolerance of The “Triple Oral Therapy” versus “anti-TNF plus Methotrexate” in Rheumatoid Arthritis with Inadequate Response To Methotrexate: A Systematic Literature Review
Authors: J. Mary, M. Debandt, C. Lukas, J. Morel, B. Combe
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> For patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX), there is some uncertainty about the relative effectiveness of combination of conventional DMARDs compared with combination of TNF inhibitors and MTX, as second line therapy. <h3>Objectives</h3> To compare efficacy and tolerance of triple oral DMARD therapy versus anti-TNF associated with MTX in patients with RA after MTX failure. <h3>Methods</h3> A systematic search of literature up to Mars 2014 was performed, in Medline, Embase, the Cochrane library and abstracts from the ACR and EULAR congresses from 2006 to 2013. Studies were included if they were randomised and controlled trial in patients receiving a triple oral combination therapy (MTX + sulfasalasine + hydroxychloroquine) compared with biologic agents plus methotrexate. Treatment effects on disease activity (DAS 28), American College of Rheumatology and the European League Against Rheumatism response criteria and structural damage using Sharp score were studied. <h3>Results</h3> Our search identified 263 articles, among them only 5 responded to the selection criteria. At six months and two years, there is a significantly larger number of participants achieving an ACR 70 response in the anti-TNF group. At one year, a significantly higher percentage of patients in the anti-TNF group reached a good EULAR response. Patients treated with TT have a significantly greater increase in modified Sharp than patients treated with MTX-infliximab at two years. Analysis based on ACR-EULAR response criteria, the DAS 28 score and Sharp score were in favor of anti-TNF combined with MTX. There was no difference between treatments on functional disability (HAQ) and rates of adverse events. <h3>Conclusions</h3> In patients with RA in whom MTX has failed, addition of tumour necrosis factor antagonist to MTX is a valid option with better clinical outcomes and better radiographical results. Addition treatment with DMARDs is an appropriate treatment option in the absence of poor prognostic factors and/or in case of TNF inhibitors contraindications in a health-economic restreint context. <h3>Disclosure of Interest</h3> None declared
The RIG-I Agonist 3pRNA Synergizes with Checkpoint Blockade in Cancer Immunotherapy
Authors: Simon Heidegger, Diana Kreppel, Michael Bscheider, Alexander Wintges, Sarah Bek, Martina Schmickl, Jürgen Ruland, Christian Peschel, Marcel van den Brink, Tobias Haas, Hendrik Poeck
Journal: Blood (2015)
IKZF1 and CRLF2 Gene Alterations Correlate with Poor Prognosis in BCR-ABL1-Negative High Risk B-Cell Precursor Acute Lymphoblastic Leukemia
Authors: Yuka Yamashita, Akira Shimada, Tomomi Yamada, Kazutaka Yamaji, Toshinari Hori, Masahito Tsurusawa, Arata Watanabe, Atsushi Kikuta, Keiko Asami, Keizo Horibe
Journal: Blood (2011)
PWE-039 The Interaction between The Hypoxia Inducible Factor-1Α (HIF-1Α) and ERBB Signalling Pathways in Colorectal Liver Metastases (CRLM)
Authors: PN Siriwardana, JE Barrett, T Luong, J Watkins, S Singh, P Kim, D Hochhauser, A Harris, T Ng, BR Davidson
Journal: Gut (2016)

<h3>Introduction</h3> Tumour hypoxia is associated with reduced survival by activating multiple molecular pathways such as, but not exclusively, HIF-1α and mTOR/AKT/PI3K pathways. It is also known to cause overexpression of Epidermal Growth Factor (EGFR)/HER1 in human cancer. HER2 (neu) signalling increases the rate of Hypoxia-Inducible Factor 1α (HIF-1α) synthesis. Overexpression of Erbb3/HER3 and Erbb4/HER4 is associated with a higher recurrence rate of stage 2 and 3 colorectal cancer. The aim of this study was to analyse the relationship between the expression of HIF-1α and members of the ErbB pathway in CRLM utilising a novel proteomic based collaborative Enzyme Enhanced Reactive (CEER) immunoassay. <h3>Methods</h3> Protein lysates of from fresh frozen biopsies and formalin fixed paraffin sections of CRLM from 18 patients who had not undergone neoadjuvant chemotherapy prior to a potentially curative hepatectomy for CRLM were analysed. When multiple metastases were present biopsies and sections were obtained from the largest metastasis. CEER immunoassay was performed on the protein lysates to quantify the phosphorylated and non-phosphorylated forms of receptors; ErbB family receptors (HER1/EGFR, HER2/c-neu, HER3, HER4) and cMET, and phosphorylated downstream ErbB pathway factors AKT, PRAS, RSP6, ERK, and RSK, and CK. Immunostaining was performed on formalin-fixed-paraffin-embedded CRLM sections for HIF-1α. ErbB pathway factor quantification was segregated according to the HIF-1α expression status; HIF-1α +ve and HIF-1α -ve <h3>Results</h3> HIF-1α was expressed in 15 (83%) of tumours. There was no significant difference between the expression of phosphorylated ‘receptors’, and phosphorylated forms AKT, PRAS, RSP6, ERK, MEK, and PI3K between the HIF-1α +ve and HIF-1α –ve groups. HER3 and IGF1R were higher; (median µm: range; 87 [74–344] vs 222 [60–404]) and (115 [85–206] vs 186 [90–285]) respectively in the HIF-1α +ve group, HER1, HER2, PI3K and CK levels were lower; (108 [40–316] vs 36 [22–46]), (698 [523–870] vs 481 [288–709]), (5338 [3334–6689] vs 2719 [1790–4193]), (5383 [1826–9799] vs 2719 [1789–4193]) respectively in the HIF-1α +ve group. Although a trend was observed, the difference did not reach statistical significance. <h3>Conclusion</h3> HIF-1α may have a role in the overexpression of HER3 and IGF1R overexpression in CRLM. More research is needed to establish this interrelationship which would help in molecular based therapeutics for CRLM. <h3>Disclosure of Interest</h3> None Declared
Severe Impairment of γ-Globin Gene Silencing in an Asymptomatic Adult Patient Homozygous for the Codon 8 (–AA) Frame-Shift β0-Thalassemia Mutation
Authors: Andrew Campbell, Hong-yuan Luo, Katherine Benson, Lance Davis, Patrick G. Gallagher, Martin H. Steinberg, Peter Fraser, Bernard G. Forget, David H.K. Chui
Journal: Blood (2012)
PTU-095 30-Day Mortality Following PEG Insertion: Could the Sheffield Gastrostomy Score Require Modification?
Authors: D Mansour, C Page, S Whiteway, N Thompson, JS Leeds
Journal: Gut (2016)

<h3>Introduction</h3> Percutaneous endoscopic gastrostomy (PEG) insertion is a valuable means of providing enteral nutrition. Previous studies have identified risk factors for poor outcomes and a scoring system devised. Further studies have shown other variables might be important including CRP and neutrophil-lymphocyte ratio (NLR). This study aimed to externally validate the score and analyse for additional variables associated with 30 day mortality. <h3>Methods</h3> Retrospective review of new PEG insertions in our institute between July 2009 to October 2015. Patient demographics, indication for PEG insertion, bioprofile, ASA grade and survival were recorded. The Sheffield Gastrostomy score (SGS) and the NLR were then calculated for each patient. Univariate analysis was performed and receiver operating characteristic (ROC) curves constructed to assess the discriminative ability of the scoring system. <h3>Results</h3> 171 PEG insertions (median age 73 years, 91 males) were included. Indication for PEG was Stroke (50), Cancer (30), Neurological (24), Dementia (5), Other (58) and not stated (4). Univariate analysis showed that 30 day mortality was associated with ASA grade 3–4 (p = 0.026) and NLR (p = 0.012) and a trend towards age &gt; 70 (p = 0.085) and low albumin levels (p = 0.058). For each increasing SGS gradation mortality rose, with 5.3% of those scoring zero dying compared to 38.5% scoring three. The area under the ROC curve was 0.617 (95% confidence interval 0.534–0.695, p = 0.04) showing reasonable discrimination. <h3>Conclusion</h3> The SGS displayed reasonable predictive ability in this external sample but identified further predictors (ASA grade and NLR). This suggests that the SGS requires remodelling with additional variables identified from a large, multicentre prospective study. <h3>Disclosure of Interest</h3> None Declared